The Science Behind Anti-Stress Please

Ashwagandha is the most thoroughly trialled adaptogen in the stress literature, and KSM-66 is its most studied standardised root extract. Every trial cited here used oral capsules.

The reference trial is Chandrasekhar, Kapoor and Anishetty (2012). Sixty-four adults with a history of chronic stress were randomised to 300 mg of a high-concentration, full-spectrum root extract twice daily (600 mg/day) or placebo for 60 days, double-blind. Serum cortisol fell by 27.9 percent in the treatment arm versus 7.9 percent under placebo (P = 0.0006). Perceived Stress Scale and General Health Questionnaire-28 scores improved significantly against placebo across all subscales.

Salve et al. (2019) compared 250 mg/day and 600 mg/day of KSM-66 against placebo in healthy adults under chronic stress, double-blind and randomised. Both doses significantly reduced Perceived Stress Scale scores and serum cortisol versus placebo, with the larger effect at 600 mg. No adverse events were reported.

Lopresti et al. (2019) randomised 60 adults to 240 mg/day of a different standardised extract (Shoden) or placebo. Morning cortisol fell significantly (P < 0.001), DHEA-S fell (P = 0.004), and Hamilton Anxiety Rating Scale scores improved.

Langade et al. (2019) tested 300 mg twice daily for 10 weeks in 60 people with insomnia and anxiety and reported significant improvements in sleep onset latency, sleep efficiency, Pittsburgh Sleep Quality Index and HAM-A scores.

Pooling the randomised trials, Akhgarjand et al. (2022) reported a standardised mean difference of -1.55 for anxiety (95% CI -2.37 to -0.74) and -1.75 for stress (95% CI -2.29 to -1.22). The dose-response analysis placed the useful range for stress at 300 to 600 mg per day.

Four independent randomised, double-blind, placebo-controlled trials, three of them measuring cortisol as an objective biomarker rather than relying on questionnaires alone, is a body of evidence very few botanicals in this category can match.

Rhodiola rosea is an arctic adaptogen with randomised, double-blind, placebo-controlled human evidence in stress-related fatigue. All trials used oral tablets or capsules.

Olsson, von Scheele and Panossian (2009) randomised 60 adults meeting Swedish national diagnostic criteria for fatigue syndrome to 576 mg/day of the standardised extract SHR-5 or placebo for 28 days. Fatigue and burnout scores improved, attention on a computerised performance test improved, and the saliva cortisol response to awakening was blunted relative to placebo - an objective endocrine measure alongside the questionnaires.

Darbinyan et al. (2000) ran a double-blind, placebo-controlled crossover trial in healthy physicians working night duty, using 170 mg/day of SHR-5. A composite Total Fatigue Index covering associative thinking, short-term memory, calculation, concentration and audio-visual perception improved significantly against placebo during the first two-week period.

The two trials converge on the same domain from different directions: a clinical fatigue population over four weeks, and healthy high-performing adults under acute occupational stress.

Holy basil (Ocimum tenuiflorum, also written Ocimum sanctum, tulsi) has two reasonably sized randomised, double-blind, placebo-controlled trials in stressed adults. Both used oral capsules.

Saxena et al. (2012) randomised 150 adults with general stress symptoms (71 to the extract, 79 to placebo) to 1200 mg/day of the standardised extract OciBest or placebo for six weeks. The extract group showed a 39 percent greater reduction in overall stress symptom scores than placebo, roughly 1.6 times the placebo response. Individual symptoms improved significantly at P <= 0.05, including forgetfulness (from 1.32 +/- 0.19 to 0.32 +/- 0.08), exhaustion, sleep problems and sexual problems. No adverse effects were reported in either arm.

Lopresti et al. (2022) randomised 100 stressed adults to 250 mg/day of the standardised extract Holixer or placebo for eight weeks. Hair cortisol at week 8 was significantly lower in the treatment arm (269.68 pg per 50 mg, 95% CI 162.61 to 447.26) than under placebo (789.89 pg per 50 mg, 95% CI 228.53 to 1407.93), p = 0.025. Perceived Stress Scale scores fell 37 percent from baseline in the treatment arm versus 19 percent under placebo (between-group p = 0.003). Athens Insomnia Scale scores fell 48 percent versus 27 percent (between-group p = 0.025).

Earlier work by Bhattacharyya et al. (2008) in generalised anxiety disorder used 500 mg twice daily for 60 days and reported significant reductions in anxiety, stress and depression scores.

Two independent double-blind trials, one of them using an objective biomarker - hair cortisol, which integrates exposure over months rather than capturing a single moment - rather than questionnaires alone, is a stronger record than most botanicals in this category can show.

L-theanine is a non-protein amino acid found almost exclusively in tea. It is one of the few ingredients in this category with acute, mechanistically plausible and repeatedly replicated human data. All trials used oral capsules or drinks.

White et al. (2016) ran a randomised, double-blind, placebo-controlled crossover trial in 34 healthy adults using a nutrient drink containing 200 mg L-theanine. Subjective stress in response to a multitasking cognitive stressor was significantly reduced one hour after dosing, and the salivary cortisol response to the stressor was significantly reduced three hours after dosing. Magnetoencephalography showed increased alpha-band oscillatory power, consistent with the relaxed-but-alert state L-theanine is associated with - a measured brain-activity correlate, not an inferred one.

Hidese et al. (2019) randomised 30 healthy adults to 200 mg/day L-theanine or placebo for four weeks in a crossover design. Stress-related symptom scores improved: Self-rating Depression Scale, State-Trait Anxiety Inventory trait anxiety, and the Pittsburgh Sleep Quality Index subscales for sleep latency, sleep disturbance and use of sleep medication all decreased relative to placebo. Verbal fluency and executive function scores also improved.

Haskell et al. (2008) tested 250 mg L-theanine and 150 mg caffeine alone and in combination in a randomised, double-blind, balanced crossover study. The combination significantly improved accuracy on an attention-switching task and reduced susceptibility to distraction, an effect that neither compound produced as cleanly on its own. This is the pharmacological basis for the theanine-plus-caffeine pairing that occurs naturally in tea.

The consistent finding across the literature is an acute calming and attention-stabilising effect at 200 to 400 mg by mouth, replicated by independent groups using both subjective and objective measures.

Magnesium is an essential mineral and a cofactor for more than 300 enzymatic reactions, including steps involved in HPA-axis regulation and NMDA receptor function. It is the mineral backbone of this formula, and the one active here whose role in the stress response is biochemical rather than botanical.

Boyle, Lawton and Dye (2017) systematically reviewed 18 controlled trials of magnesium supplementation with subjective anxiety or stress outcomes. Four of eight trials in anxious samples, four of seven in premenstrual syndrome samples and one of two in hypertensive samples reported a benefit. The authors concluded that the existing evidence is suggestive of a beneficial effect in anxiety-vulnerable populations. All of those trials used oral magnesium.

Magnesium glycinate (magnesium bisglycinate) is the form used here for its tolerability profile: the glycinate salt is associated with less osmotic diarrhoea than magnesium oxide or citrate, and the counter-ion is not inert - glycine is itself an inhibitory neurotransmitter, acting on the same calming axis as the rest of this formula.